三重激动剂 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== Other == HMF is an intermediate in the titration of hexoses in the Molisch's test. In the related Bial's test for pentoses, the hydroxymethylfurfural from hexoses may give a muddy-brown or gray solution, but this is easily distinguishable from the green color of pentoses. Acetoxymethyl furfural (AMF) is also bio-derived green platform chemicals as an alternative to HMF.
3'-end Also three-prime end. One of two ends of a single linear strand of DNA or RNA, specifically the end at which the chain of nucleotides terminates at the third carbon atom in the furanose ring of deoxyribose or ribose (i.e. the terminus at which the 3' carbon is not attached to another nucleotide via a phosphodiester bond; in vivo, the 3' carbon is often still bonded to a hydroxyl group). By convention, sequences and structures positioned nearer to the 3'-end relative to others are referred to as downstream. Contrast 5'-end.
From this, a pH, or acidity, can be calculated for aqueous solutions of bases. A base is also defined as a molecule that has the ability to accept an electron pair bond by entering another atom's valence shell through its possession of one electron pair. There are a limited number of elements that have atoms with the ability to provide a molecule with basic properties. Carbon can act as a base as well as nitrogen and oxygen. Fluorine and sometimes rare gases possess this ability as well. This occurs typically in compounds such as butyl lithium, alkoxides, and metal amides such as sodium amide. Bases of carbon, nitrogen and oxygen without resonance stabilization are usually very strong, or superbases, which cannot exist in a water solution due to the acidity of water. Resonance stabilization, however, enables weaker bases such as carboxylates; for example, sodium acetate is a weak base.
Although councils had already suffered deep cuts under Labour in the 1970s, Heseltine was under pressure from Thatcher and from Conservative MPs and newspapers to cut more. Heseltine's initial suggestion, that councils who wanted to increase the rates be forced to submit to re-election, was rejected by the Cabinet, in favour of a proposal that such increases be put to referendum (in Coventry, voters had recently voted by over 7:1 for spending cuts rather than a supplementary rate increase). This proposal in turn was attacked by Conservative backbenchers, both as an infringement of council freedom and a risky precedent for national taxation, both in the Environment Committee and in the debate on a bill which Heseltine introduced and had to withdraw. Heseltine then banned supplementary rates and imposed stiffer sanctions on overspending councils. Thatcher's 1974 pledge to abolish the rates and replace them with a new form of local government funding was still in force. However, the 1979 manifesto made clear that income tax cuts took priority over rates reform. Thatcher also blocked the upward revaluation of property rating values in 1982. A review of rates reform was begun in 1981, in which his junior minister Tom King personally spoke to every single backbench Conservative MP to canvass opinion about the various options. A Green Paper was produced in December 1981, recommending that no single alternative to the rates suggested itself.
Sources: en.wikipedia.org
== Related compounds == The naphthoquinones lawsone methyl ether and methylene-3,3'-bilawsone are some of the active compounds in Impatiens balsamina leaves. Juglone is a structural isomer used as a brown dye. Atovaquone is a synthetic antimicrobial agent that can be manufactured from lawsone.
Demoxytocin (INN; brand names Sandopart, Odeax, Sandopral; also known as desaminooxytocin, deaminooxytocin, 1-(3-mercaptopropanoic acid)oxytocin, and [Mpa1]OT) is an oxytocic peptide drug that is used to induce labor, promote lactation, and to prevent and treat puerperal (postpartum) mastitis (breast inflammation). Demoxytocin is a synthetic analogue of oxytocin and has similar activities, but is more potent and has a longer half-life in comparison. Unlike oxytocin, which is given via intravenous injection, demoxytocin is administered as a buccal tablet formulation. The drug was first synthesized in 1960 and was introduced into clinical practice in 1971 by Sandoz. It is marketed in several European countries, including Italy, Czech Republic, and Poland. It has the amino acid sequence Mpa-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Mpa = β-mercaptopropionic acid), and is an analogue of oxytocin wherein the leading cysteine is replaced with β-mercaptopropionic acid.
After the inauguration of Barack Obama, Bush and his family flew from Andrews Air Force Base to a homecoming celebration in Midland, Texas, and then returned to their ranch in Crawford, Texas. They bought a home in the Preston Hollow neighborhood of Dallas where they live. Bush made regular appearances at various events throughout the Dallas–Fort Worth area, including the opening coin toss at the Dallas Cowboys' first game in the new Cowboys Stadium in Arlington and an April 2009 Texas Rangers game, where he thanked the people of Dallas for helping him settle in, which was met with a standing ovation. He also attended every home playoff game during the Rangers' 2010 season and, accompanied by his father, threw out the ceremonial first pitch at the Rangers Ballpark in Arlington for Game 4 of the 2010 World Series on October 31. He also threw the first pitch in Game 1 of the 2023 World Series. On August 6, 2013, Bush was successfully treated for a coronary artery blockage with a stent. The blockage had been found during an annual medical examination. In reaction to the 2016 shooting of Dallas police officers, Bush said: "Laura and I are heartbroken by the heinous acts of violence in our city last night. Murdering the innocent is always evil, never more so than when the lives taken belong to those who protect our families and communities."
=== Natural habitat === In nature, Komagataella is found on trees, such as chestnut trees. They are heterotrophs and they can use several carbon sources for living, like glucose, glycerol and methanol. However, they cannot use lactose.
Significance of research: All experiments are carried out at 60 °C. Changes in the equilibrium constant (K) are used to determine what type of lipid interactions are occurring within the modeled membrane as well as observe liquid-ordered versus liquid-disorder regions. The value of the equilibrium constant determine the following: 1) if monomers are mixed ideally (K = 4.0) 2) when the monomers are mixed homogenously also referred to as a homo-association (K < 4.0) and 3) if the monomers have interchanged heterogeneously which is referred to as an hetero-association (K > 4.0) A plot of (K) is then created versus the cholesterol mol%. Each plot has similar trends in which the value of the equilibrium constant increased as the mol% increased with and without the presence of ethanol indicating a linear regression. Initially all the model membranes were organized in a liquid order phase but as the addition of cholesterol increase a liquid-disorder phase was observed. The following was determined regarding the liquid-order and liquid-disordered transitions during the addition of cholesterol in the presence of ethanol in each model membrane: 1) 0–15 mol% cholesterol a liquid-disordered phase was present 2) from 15 to 30 mol% there was a co-existence of both phases and 3) above 27 mole% of cholesterol the model membrane completed converted back to the original liquid-order phase within a two-hour time frame. The linear regression maxed out at 30 mol% of cholesterol.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.